GENEWIZ acquires Beckman Coulter’s genomic services business
Beckman Coulter delivers expert genomics sequencing solutions to healthcare businesses, as well as academic and government institutions worldwide.
“The genomic services business of Beckman Coulter is an ideal fit with GENEWIZ’s global strategy and expansion plans,” said Dr. Steve Sun, chairman and CEO of Suzhou, China-based GENEWIZ. “Our two companies share a common mission and vision: to offer scientists around the world consistently reliable genomics service solutions that will advance innovations and scientific discoveries.”
The synergies of this acquisition will support GENEWIZ’s global expansion strategy by leveraging Beckman Coulter’s 25-plus years of genomics expertise and capabilities. The U.S. company’s comprehensive Sanger Sequencing, Next Generation Sequencing, Bioinformatics, and CLIA/Clinical Services will complement GENEWIZ’s existing genomics services. With an international presence in the U.S. and a Pan-European presence centered in the U.K., Beckman Coulter presents an immediate opportunity to strengthen GENEWIZ’s global access and value to customers through a stronger network of global labs and office locations in the U.S., U.K., China and Japan.
“Their proven leadership and experienced team of industry experts have built an efficient workflow that allows for the delivery of quality and timely results to its customers,” said Sun. “The integration of these two businesses will allow for an increased level of service and value to customers worldwide. We look forward to working with the talented Beckman Coulter team to best serve our customers, and be an instrumental part of the future growth of GENEWIZ.”
The two companies will collaboratively align to ensure there is a seamless transition for both organizations and its customer base. The agreement has been approved by the boards of directors of both companies and is effective immediately.
In addition to its locations in China, GENEWIZ has several in the U.S., as well as others in London and Tokyo.